On June 28, the Eribulin Mesilate Injection developed by Qingfeng Pharmaceutical Group was approved for marketing by the U.S. Food and Drug Administration (FDA), making Qingfeng Pharmaceutical the ...
On June 28, the Brivaracetam tablets (trade name: Qingruitan®) developed by Qingfeng Pharmaceutical Group were officially approved for marketing by the National Medical Products Administration. The...
On November 24, the official website of the Center for Drug Evaluation (CDE) of the NMPA announced that the marketing application for GP681 tablets, a Class 1 innovative chemical drug registered an...
On September 26, the enzalutamide API and soft capsule developed by Qingfeng Pharmaceutical, a subsidiary of Qingfeng Pharmaceutical Group, were approved for marketing by the U.S. Food and Drug Adm...
From August 21 to 25, 2023, the U.S. Food and Drug Administration (FDA) conducted a five-day on-site audit of Qingfeng Pharmaceutical's enzalutamide API and the company's overall production quality...
On August 3, the NMPA approved the marketing of Rabeprazole Sodium Enteric-coated Tablets developed by Shanxiang Pharmaceutical, a subsidiary of Qingfeng Pharmaceutical Group. This is the second pr...
Recently, Tedizolid Phosphate for Injection, a drug developed by Qingfeng Pharmaceutical for the treatment of acute bacterial skin and skin soft tissue infections, was officially approved for marke...
Recently, the "Smooth Anti-Inflammation and Easy Breathing" - Chinese and Western Integration Summit Forum on Respiratory Infectious Diseases·Tianjin Station hosted by Qingfeng Pharmaceutical came ...
A few days ago, the official website of the NMPA released the drug approval certificate. The information showed on March 22, the Lenvatinib capsule developed by Hangzhou Qingyue and Shanxiang pharm...
On August 1, 2021 (the 38th) national pharmaceutical industry information annual conference was grandly opened in Jinan, Shandong Province. The conference officially released the list of the best ...
On June 24, China National Intellectual Property Administration officially announced the list of winners of the 22nd China Patent Award. Qingfeng Pharma. new method for synthesizing lacosamide won ...
On February 3, Shanghai Yangguang Pharmaceutical Purchasing Network officially released the bidding results of fourth batch of national volume based procurement. Jiangxi Shanxiang Pharmaceutical Co...
On November 4, Xinkang® Lacosamide injection, declared by Jiangxi Qingfeng Pharmaceutical Co., Ltd., was approved by NMPA and deemed to have passed the consistency evaluation. This is the first ...
On September 10, Shanghai Denovo PharmaceuticalTechnology Co., Ltd., a subsidiary of Qingfeng Pharmaceutical Group, held aTLR8 agonist DN1508052-01 Phase I clinical trial kick-off meeting at Shangh...
On August 25, 2020, our clinical research team held a GP681 clinical study kick-off meeting in Shanghai Xuhui District Central Hospital, marking that our innovative drug GP681 has officially ...
On August 30th, the high-profile "2019 China Pharmaceutical Industry Top 100 List" was grandly released in Zhuhai. Qingfeng Pharmaceutical Group was once again nominated as the 64th place among ...
The Class 4 chemical generic Sorafenib tosylate tablets (trade name: Ligesitai®) developed by Jiangxi Shanxiang Pharmaceutical Co., Ltd., a subsidiary of Qingfeng Pharmaceutical Group, were ...
On July 8, Bangkaxin® (Esomeprazole Magnesium Enteric-coated Tablets) declared by Qingfeng Pharmaceutical Group and Jiangxi Shanxiang Pharmaceutical Co., Ltd. was approved by NMPA. The successful ...
On May 12, the National Medical Products Administration (NMPA) formally approved the application of Shikang® Apixaban tablets from Jiangxi Qingfeng Pharmaceutical.
